Sublingual spray drug delivery of ketorolac-loaded chitosan nanoparticles

References

• Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53:139–188.
   PubMed Web of Science ®Google Scholar
• Buckley MM-T, Brogden RN. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990;39:86–109.
   PubMed Web of Science ®Google Scholar
• Litvak K, McEvoy G. Ketorolac, an injectable nonnarcotic analgesic. Clin Pharm. 1990;9:921–935.
   PubMedGoogle Scholar
• Forrest JB, Heitlinger EL, Revell S. Ketorolac for postoperative pain management in children. Drug Saf. 1997;16:309–329.
   PubMed Web of Science ®Google Scholar
• Smith L, Carroll D, Edwards J, et al. Single-dose ketorolac and pethidine in acute postoperative pain: systematic review with meta-analysis. Br J Anaesth. 2000;84:48–58.
   PubMed Web of Science ®Google Scholar
• Zhou TJ, Tang J, White PF. Propacetamol versus ketorolac for treatment of acute postoperative pain after total hip or knee replacement. Anesth Analg. 2001;92:1569–1575.
   PubMed Web of Science ®Google Scholar
• Sinha V, Kumar R, Singh G. Ketorolac tromethamine formulations: an overview. Expert Opin Drug Deliv. 2009;6:961–975.
   PubMed Web of Science ®Google Scholar
• Friedman BW, Garber L, Yoon A, et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014;82:976–983.
   PubMed Web of Science ®Google Scholar
• Kelley NE, Tepper DE. Rescue therapy for acute migraine. Part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache. 2012;52:467–482.
   PubMed Web of Science ®Google Scholar
• Iorno V, Landi L, Di Pasquale R, et al. Comparison of intravenous ketorolac with or without paracetamol in postoperative pain control following ambulatory surgery. Curr Med Res Opin. 2013;29:1685–1690.
   PubMed Web of Science ®Google Scholar
• Wang Z, Chow MS. Overview and appraisal of the current concept and technologies for improvement of sublingual drug delivery. Ther Deliv. 2014;5:807–816.
   PubMedGoogle Scholar
• Goswami T, Jasti BR, Li X. Sublingual drug delivery. Crit Rev Ther Drug Carrier Syst. 2008;25:449–484.
   PubMed Web of Science ®Google Scholar
• Puglia C, Filosa R, Peduto A, et al. Synthesis, physicochemical properties and in vitro permeation studies of new ketorolac ester derivatives. Curr Drug Deliv. 2007;4:205–210.
   PubMedGoogle Scholar
• Vatsaraj N, Zia H, Needham T. Formulation and optimization of a sustained-release tablet of ketorolac tromethamine. Drug Deliv. 2002;9:153–159.
   PubMed Web of Science ®Google Scholar
• Madhav NS, Shakya AK, Shakya P, et al. Orotransmucosal drug delivery systems: a review. J Control Release. 2009;140:2–11.
   PubMed Web of Science ®Google Scholar
• Ilium L. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998;15:1326–1331.
   PubMed Web of Science ®Google Scholar
• Sonaje K, Chuang E, Lin K, et al. Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations. Mol Pharm. 2012;9:1271–1279.
   PubMed Web of Science ®Google Scholar
• Baltzley S, Mohammad A, Malkawi AH, et al. Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles. AAPS PharmSciTech. 2014;15:1598–1602.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huo M, Zhou J, et al. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Prog Biomed. 2010;99:306–314.
   PubMed Web of Science ®Google Scholar
• Radwan M, AlQuadeib B, Aloudah N, et al. Pharmacokinetics of ketorolac loaded to polyethylcyanoacrylate nanoparticles using UPLC MS/MS for its determination in rats. Int J Pharm. 2010;397:173–178.
   PubMed Web of Science ®Google Scholar
• Li C, Li C, Liu Z, et al. Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. Int J Pharm. 2014;474:123–133.
   PubMed Web of Science ®Google Scholar
• Santus G, Rivolta R, Bottoni G, et al. Nasal formulations of ketorolac tromethamine: technological evaluation-bioavailability and tolerability in rabbits. Farmaco. 1993;48:1709–1723.
   PubMedGoogle Scholar
• Mroszczak EJ, Lee FW, Combs D, et al. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metabol Dispos. 1987;15:618–626.
   PubMed Web of Science ®Google Scholar
• Brocks DR, Jamali F. Clinical pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet. 1992;23:415–427.
   PubMed Web of Science ®Google Scholar
• Al-Ghananeem AM. Ketorolac sublingual spray for the treatment of pain. US 20090246273 A1. 2009.
   Google Scholar
• McAleer SD, Majid O, Venables E, et al. Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. J Clin Pharmacol. 2007;47:13–18.
   PubMed Web of Science ®Google Scholar
• Moodie JE, Brown CR, Bisley EJ, et al. The safety and analgesic efficacy of intranasal ketorolac in patients with postoperative pain. Anesth Analg. 2008;107:2025–2031.
   PubMed Web of Science ®Google Scholar
• Drover DR, Hammer GB, Anderson BJ. The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. Anesth Analg. 2012;114:1270–1276.
   PubMed Web of Science ®Google Scholar
• Bullingham R, Juan A. Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. Drugs Aging. 2012;29:899–904.
   PubMed Web of Science ®Google Scholar
• Pérez-Urizar J, Aguilar-Cota ME, Herrera JE, et al. Comparative bioavailability of ketorolac tromethamine after intramuscular and sublingual administration. Proceedings of the Western Pharmacology Society; 2002. Seattle (WA): The Society. p. 6–7.
   Google Scholar
• Galán-Herrera JF, Poo JK, Maya-Barrios JA, et al. Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: a randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers. Clin Ther. 2008;30:1667–1674.
   PubMed Web of Science ®Google Scholar
• Chasseaud L, Darragh A, Doyle E, et al. Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations. J Pharm Sci. 1984;73:699–701.
   PubMed Web of Science ®Google Scholar